Executive Coaching Network

Return to MassNextGen

Sangeeta Bhatia

Director of Laboratory for Multiscale Regenerative Technologies, MIT

Sangeeta Bhatia is the Director of Laboratory for Multiscale Regenerative Technologies at MIT, in addition to a cancer research, professor, and biotech entrepreneur. Sangeeta is trained as both a physician and engineer at Harvard, MIT, and Brown University. Her lab leveraged “tiny technologies” of miniaturization to yield inventions with new applications in tissue regeneration, stem cell differentiation, medical diagnostics, predictive toxicology and drug delivery. She and her trainees have launched more than 10 biotechnology companies to improve human health. Sangeeta has received many honors including the Lemelson-MIT Prize, known as the ‘Oscar for inventors,’ and the Heinz Medal for groundbreaking inventions and advocacy for women in STEM fields. 

Kevin Bitterman

Partner, Atlas Ventures

As Partner at Atlas Ventures, Kevin Bitterman is focused on creating and investing in companies that translate groundbreaking science into innovative medicines. Kevin is active in the local life science and healthcare start up community and presently serves on the Scientific Advisory Board of the Massachusetts Life Sciences Center and as Board Chair of the New England Venture Capital Association (NEVCA). He was founding CEO of Editas Medicine, Morphic Therapeutic, and Visterra, in addition to co-founded Genocea Biosciences. He previously served as Director of several companies, including Kala Pharmaceuticals, a publicly traded company, and Taris Biomedical, which was acquired by Allergan. Prior to joining Atlas, Kevin was a Partner on the Healthcare Team at Polaris Partners.

Jim Coccia

Vice President, U.S. Market Access, Takeda

Today, the measure of success of any medical drug, device, or diagnostic is not measured on its clinical attributes, but whether or not it achieves reimbursement.   Without payment, even the best product has no future and this planning should begin with clinical development.  As Vice President for Market Access and Pricing for Takeda Oncology, Jim Coccia is responsible for ensuring payment and access through a therapies life cycle.  With over 25 years’ experience in the field of market access, Jim has worked with dozens of product in pharma, biotech, and medical device fields and has launched products that have redefined national policy.  Jim has broad knowledge and perspective on how drug pricing and access have developed over the last two decades and what the future may bring.

Bonnie Fendrock

CEO and Co-founder Cyta Therapeutics, Inc.

Bonnie Fendrock is an advisor at Red Sky Partners, a boutique consulting firm providing corporate development, product strategy and leadership support to life sciences companies. She is also the founding CEO of Cyta Therapeutics, an early stage spin-out from UMass, Amherst. Bonnie was CEO, Co-founder and Board Member of Hepregen Corporation, a venture backed, commercial stage, MIT spin-out. In 2012, Bonnie was honored along with other innovation leaders as one of the Mass High Tech ‘Women to Watch’. With a general management background, Bonnie has held roles in corporate and business development, marketing and program management from foundational and high growth biotechnology companies including Genzyme, Somatix, Genetics Institute and Acusphere. Bonnie served as a Director on the Boston Chapter Board of the Healthcare Businesswomen’s Association (HBA) for five years and volunteers as a mentor to entrepreneurs through The Deshpande Center and other organizations. Prior to business school, she worked in research and product development at Integrated Genetics and Centocor. Bonnie received a BA, Molecular Biology from Wellesley College, a MS, Interdisciplinary Science from MIT and a MBA from The Wharton School, University of Pennsylvania as a Management of Technology Fellow.

Barbara Fox

CEO of Tilos Therapeutics, Inc.

Barbara Fox is the founding CEO of Tilos Therapeutics. She has previously served as Entrepreneur-in-Residence at Partners Innovation Fund, founder and CEO of Avaxia Biologics, founder and CSO of Recovery Pharmaceuticals, VP Discovery and Immunology at ImmuLogic Pharmaceutical Corp., and Associate Professor of Rheumatology at the University Of Maryland School Of Medicine. Barbara received her AB in chemistry from Bryn Mawr, her PhD in chemistry from MIT and trained as a post-doc in cellular immunology at the National Institute of Heath. She was also an EY Entrepreneur Of The Year™ 2014 Award finalist in New England and presently serves as a Member of the Board of Directors at AnTolRx, Inc.

Luba Greenwood

Strategic Business Development and Corporate Ventures at Google, Verily

Luba Greenwood has deep industry experience and expertise in mergers and acquisitions and strategic partnerships. She recently joined Google, Verily in the Strategic Business Development and Corporate Ventures for Google Life Sciences division and was previously the Vice President of Global Mergers and Acquisitions and Business Development at Roche Diagnostics. Luba advised innovative technology companies and provided strategic counsel to global corporations. She has held leadership positions in venture investing, business development, law, consulting, and operations. Luba recently served as a Venture Partner at Colt Ventures and led the Business Development and Strategy for Pronutria, a Flagship VentureLabs company. She has held previous positions in law at Pfizer, Inc. and Wilmer Cutler Pickering Hale and Dorr, representing large multinational corporations, start-ups, private equity and venture capital funds in biotechnology, high technology, energy, and finance industries, among others. Luba is a Co-chair of MassBio’s Entrepreneur’s University, mentor for the MIT 100K Entrepreneurship Competition, a judge for MassChallenge and the Young Entrepreneurs Initiative, and on a Steering Committee of the Boston Bar Association. In 2014, she received the Science Club for Girls Catalyst Award for her commitment to fostering women talent and advocating for women in science and technology.

Paulina Hill

Principal at Polaris Partners

As Principal at Polaris Partners, Paulina Hill focusses on investments in healthcare and has served as founding CEO of Polaris-backed Marauder Therapeutics, a biotech startup based in Cambridge, MA. She presently serves on several boards, including Arsenal Medical, Faraday Pharmaceuticals and Kala Pharmaceuticals. She is an active observer on the boards of 480 Biomedical, Microchips Biotech, and Sofregen and also serves on the Capital Network’s board. Prior to joining Polaris, Paulina completed her postdoctoral fellowship in the Chemical Engineering department at MIT in Bob Langer’s lab. She is the founding President of the MIT Postdoctoral Association and served on the MIT Intellectual Property President Committee. East Carolina University honored Paulina with the Incredible Women’s Award in 2017, which is her alma mater of a quadruple major in biochemistry, neuroscience, biology, and chemistry.

Pam Randhawa

Founder and CEO of Empiriko

Pam Randhawa is Founder and CEO of Empiriko, an integrated precision medicine company focused on early disease detection, prognosis, prediction and ongoing therapeutic monitoring. Pam has 20 years of experience in the healthcare and life sciences industries with expertise ranging from policy, corporate strategy, product development, analytics and marketing for Fortune 500 companies, startups and government. Prior to founding Empiriko, Pam co-founded AgroGreen Biofuels, an alternative biofuels technology company from plant waste. Pam has previously served as VP of Strategic Development at Sermo, in addition to the VP of Global Marketing at Phase Forward (acquired by Oracle), a leader in Electronic Data Capture (EDC), management and drug safety for clinical trials. She has also served as an independent consultant to the State of Ohio, Department of Health, where she led a statewide taskforce focusing on the Health Status of Ohioans for the State Health Plan, and developed a 5-point plan to improve public health in Ohio.

Connect With Us

Blog Facebook LinkedIn Twitter